CancerNCT03186703
Evaluating the Impact of the McMaster Optimal Aging Portal on Cancer Prevention Behaviours in Underserved Populations
A study testing Tailored knowledge translation in people with Cancer, run by McMaster University at 1 site in Canada.
Trial summary
The goal of the McMaster Optimal Aging Portal is to be a trustworthy source for health information. The Portal team can see (through measuring analytics of website use) that thousands of people are using the Portal and the knowledge-sharing strategies in place (email alerts, Twitter and Facebook), with many more users… Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cancer
- What is being tested?
- Tailored knowledge translation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 549 participants
- Where
- 1 siteCanada
- Study dates
- 1 Oct 2017to 31 Dec 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- English speaking
Who cannot join
- Previous cancer diagnosis
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluating the Impact of the McMaster Optimal Aging Portal on Knowledge, Behavioural Intentions and Health Behaviours Related to Cancer Risk in Underserved Populations.
The goal of the McMaster Optimal Aging Portal is to be a trustworthy source for health information. The Portal team can see (through measuring analytics of website use) that thousands of people are using the Portal and the knowledge-sharing strategies in place (email alerts, Twitter and Facebook), with many more users added each month. Previous studies have measured the quality and trustworthiness of health information available online; others have studied the numbers and populations who use different types of information and how easy it is to use and understand. This study builds on that knowledge to find out: if easy-to-understand evidence-based messages reach members of the public, do these messages change what people know and think to do to stay healthy (in this case, what they know and think to do to lower their risk of cancer)?
Read the detailed description
Half of cancers are preventable through lifestyle modification such as smoking cessation, healthy eating, increasing physical activity and reducing alcohol intake; however, few Canadians engage in behaviours that are in line with cancer prevention guidelines. This may be in part due to lack of access to evidence-based information and the mixed messages on effective cancer prevention strategies that are propagated in the popular media.
The McMaster Optimal Aging Portal (the Portal) is a knowledge translation (KT) tool launched in 2014 to increase public access to trustworthy health information. Citizen-friendly content (blog posts, evidence summaries, web resource ratings) provide easy-to-read 'bottom line' messages appropriate for all audiences. Investigators would now like to know if and how KT strategies used to disseminate citizen-targeted information on cancer prevention impact knowledge, behavioural intentions and health behaviours of Canadian adults.
This study will use a sequential mixed-methods design consisting of a two-arm randomized controlled trial (RCT) and a qualitative process study to explore RCT findings in depth. This formative approach will allow for a deeper analysis of the outcomes of interest (knowledge, intentions and behaviours), and the KT process. Following baseline data collection, eligible participants will be randomized to a 12-week intervention or control group.
During the intervention, participants will have access to the Portal, be invited to follow a Twitter and Facebook feed, and receive tailored weekly email alerts including blog posts and evidence summaries on cancer prevention. Control group participants will have access the Portal in a 'self-serve' fashion, but will not receive KT strategies.
- Conditions
- Cancer
- Being tested
- Tailored knowledge translation
- Keywords
- Cancer prevention, Knowledge translation, Physical activity, Diet, Alcohol, Smoking
- Medical subject headings
- Neoplasms, Motor Activity, Smoking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tailored knowledge translationBehavioural
Tailored knowledge translation strategies specific to evidence-based cancer prevention recommendations
| Study group | Role | What they receive |
|---|---|---|
| Tailored knowledge translation | Experimental | During the 12-week intervention, intervention group participants will have access to the Portal and will receive targeted weekly email alerts including blog posts and evidence summaries relevant to cancer prevention and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant cancer prevention information. Receives: Behavioral: Tailored knowledge translation |
| Control | No intervention | Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Website engagement
Number of clicks
Measured: 12 weeks
Email engagement
Number of clicks
Measured: 12 weeks
Social media engagement
Number of clicks
Measured: 12 weeks
Secondary outcomes (8)
Knowledge questionnaire
Participants knowledge of cancer prevention recommendations and guidelines
Measured: 12 weeks, 3-months post-intervention
Beliefs questionnaire
Participants beliefs about the importance of lifestyle in prevention cancer
Measured: 12 weeks, 3-months post-intervention
Intentions questionnaire
Participants intentions to engage in lifestyle behaviours in line with cancer prevention guidelines
Measured: 12 weeks, 3-months post-intervention
Godin leisure time exercise questionnaire
Physical activity
Measured: 12 weeks, 3 months post-intervention
Dietary Screener Questionnaire
Dietary intake
Measured: 12 weeks, 3 months post-intervention
Tobacco Questions for Surveys, World Health Organization
Current smoking behaviour
Measured: 12 weeks, 3 months post-intervention
Seven-day recall alcohol
Alcohol intake
Measured: 12 weeks, 3 months post-intervention
Participant satisfaction
Collected using qualitative interviews
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2017
- Study start1 Oct 2017
- Primary completion1 Sep 2018
- Study completion31 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by McMaster UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 549 participants (actual)
Sponsor and investigators
- Lead sponsor
- McMaster University
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Responsible party
- Sponsor
- Investigators
- Maureen Dobbins, RN, PhD, Principal investigator, McMaster University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03186703
- Sponsor's protocol ID
- 316590
- Status last verified
- Mar 2019
- First submitted
- 7 Apr 2017
- Last updated
- 21 Feb 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Neil-Sztramko SE, Belita E, Levinson AJ, Boyko J, Dobbins M. Evaluation of an online knowledge translation intervention to promote cancer risk reduction behaviours: findings from a randomized controlled trial. BMC Cancer. 2019 Nov 21;19(1):1138. doi: 10.1186/s12885-019-6361-2.
PubMed 31752751
Study at a glance
From the registry record, last updated by the sponsor on 21 Feb 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating the Impact of the McMaster Optimal Aging Portal on Knowledge, Behavioural Intentions and Health Behaviours Related to Cancer Risk in Underserved Populations.
- ClinicalTrials.gov ID
- NCT03186703
- Acronym / sponsor ID
- 316590
- Conditions
- Cancer
- Keywords
- Cancer prevention, Knowledge translation, Physical activity, Diet, Alcohol, Smoking
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 549 participants (actual)
- Lead sponsor
- McMaster UniversityUniversity, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Study start
- 1 Oct 2017 (actual)
- Primary completion
- 1 Sep 2018 (actual)
- Study completion
- 31 Dec 2019 (actual)
- First posted
- 14 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of the McMaster Optimal Aging Portal is to be a trustworthy source for health information. The Portal team can see (through measuring analytics of website use) that thousands of people are using the Portal and the knowledge-sharing strategies in place (email alerts, Twitter and Facebook), with many more users added each month. Previous studies have measured the quality and trustworthiness of health information available online; others have studied the numbers and populations who use different types of information and how easy it is to use and understand. This study builds on that knowledge to find out: if easy-to-understand evidence-based messages reach members of the public, do these messages change what people know and think to do to stay healthy (in this case, what they know and think to do to lower their risk of cancer)?
Detailed description
Half of cancers are preventable through lifestyle modification such as smoking cessation, healthy eating, increasing physical activity and reducing alcohol intake; however, few Canadians engage in behaviours that are in line with cancer prevention guidelines. This may be in part due to lack of access to evidence-based information and the mixed messages on effective cancer prevention strategies that are propagated in the popular media.
The McMaster Optimal Aging Portal (the Portal) is a knowledge translation (KT) tool launched in 2014 to increase public access to trustworthy health information. Citizen-friendly content (blog posts, evidence summaries, web resource ratings) provide easy-to-read 'bottom line' messages appropriate for all audiences. Investigators would now like to know if and how KT strategies used to disseminate citizen-targeted information on cancer prevention impact knowledge, behavioural intentions and health behaviours of Canadian adults.
This study will use a sequential mixed-methods design consisting of a two-arm randomized controlled trial (RCT) and a qualitative process study to explore RCT findings in depth. This formative approach will allow for a deeper analysis of the outcomes of interest (knowledge, intentions and behaviours), and the KT process. Following baseline data collection, eligible participants will be randomized to a 12-week intervention or control group.
During the intervention, participants will have access to the Portal, be invited to follow a Twitter and Facebook feed, and receive tailored weekly email alerts including blog posts and evidence summaries on cancer prevention. Control group participants will have access the Portal in a 'self-serve' fashion, but will not receive KT strategies.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Tailored knowledge translation | Experimental | Behavioral: Tailored knowledge translationDuring the 12-week intervention, intervention group participants will have access to the Portal and will receive targeted weekly email alerts including blog posts and evidence summaries relevant to cancer prevention and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant cancer prevention information. |
| Control | No intervention | –Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored intervention. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- English speaking
Key exclusion criteria (1 listed)
- Previous cancer diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tailored knowledge translationTailored knowledge translation strategies specific to evidence-based cancer prevention recommendations | Behavioural | Tailored knowledge translation |
Primary outcome
Website engagement
Time frame: 12 weeks
Number of clicks
Email engagement
Time frame: 12 weeks
Number of clicks
Social media engagement
Time frame: 12 weeks
Number of clicks
8 secondary outcomes
Knowledge questionnaire
Time frame: 12 weeks, 3-months post-intervention
Beliefs questionnaire
Time frame: 12 weeks, 3-months post-intervention
Intentions questionnaire
Time frame: 12 weeks, 3-months post-intervention
Godin leisure time exercise questionnaire
Time frame: 12 weeks, 3 months post-intervention
Dietary Screener Questionnaire
Time frame: 12 weeks, 3 months post-intervention
Tobacco Questions for Surveys, World Health Organization
Time frame: 12 weeks, 3 months post-intervention
Seven-day recall alcohol
Time frame: 12 weeks, 3 months post-intervention
Participant satisfaction
Time frame: 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Feb 2020.
- Results publication: PubMed 31752751Neil-Sztramko SE, Belita E, Levinson AJ, Boyko J, Dobbins M. Evaluation of an online knowledge translation intervention to promote cancer risk reduction behaviours: findings from a randomized controlled trial. BMC Cancer. 2019 Nov 21;19(1):1138. doi: 10.1186/s12885-019-6361-2.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maureen Dobbins, RN, PhD principal investigator
McMaster University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tailored knowledge translation in people with Cancer, run by McMaster University at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Website engagement (time frame: 12 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03186703, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2020.